Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients

Figure 1

The treatment schema. Her2Bi armed ATC (aATC) were administered twice weekly for four consecutive weeks. All patients received subcutaneous IL-2 (300,000 IU/m²/day) and GM-CSF (250 μg/m²/twice weekly), beginning 3 days before the first aATC infusion and ending 1 week after the last aATC infusion. Immune testing was performed at indicated time points.